Abstract
Purpose
9-(β-D-Arabinofuranosyl)guanine (AraG) is a guanosine analog that has a proven efficacy in the treatment of T-cell lymphoblastic disease. To test the possibility of using a radiofluorinated AraG as an imaging agent, we have synthesized 2′-deoxy-2′-[18F]fluoro-9-β-D-arabinofuranosylguanine ([18F]F-AraG) and investigated its uptake in T cells.
Procedure
We have synthesized [18F]F-AraG via a direct fluorination of 2-N-acetyl-6-O-((4-nitrophenyl)ethyl)-9-(3′,5′-di-O-trityl-2′-O-trifyl-β-D-ribofuranosyl)guanine with [18F]KF/K.2.2.2 in DMSO at 85°C for 45 min. [18F]F-AraG uptake in both a CCRF-CEM leukemia cell line (unactivated) and activated primary thymocytes was evaluated.
Results
We have successfully prepared [18F]F-AraG in 7–10% radiochemical yield (decay corrected) with a specific activity of 0.8–1.3 Ci/μmol. Preliminary cell uptake experiments showed that both a CCRF-CEM leukemia cell line and activated primary thymocytes take up the [18F]F-AraG.
Conclusion
For the first time to the best of our knowledge, [18F]F-AraG has been successfully synthesized by direct fluorination of an appropriate precursor of a guanosine nucleoside. This approach maybe also useful for the synthesis of other important positron emission tomography (PET) probes such as [18F]FEAU, [18F]FMAU, and [18F]FBAU which are currently synthesized by multiple steps and involve lengthy purification. The cell uptake studies support future studies to investigate the use of [18F]F-AraG as a PET imaging agent of T cells.
References
Barrio JR, Namavari M, Phelps ME, Satyamurthy N (1996) Elemental fluorine to 8-fluoropurines in one step. J Am Chem Soc 118:10408–10411
Carson DA, Wasson DB, Esparza LM, Carrera CJ, Kipps T, Cottam HB (1992) Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′-arabinofluoro-2′-deoxyadenosine. Pro Natl Acad Sci USA 89:2970–2974
Takahashi T, Kanazawa J, Akinaga S, Tamoaki T, Okabe M (1999) Cancer antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arbionfuranosyl)adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration. Chemother Pharmacol 43:233–240
Kim CG, yang DJ, Kim EE, Cherif A, Kuang LR, Li C, Tansey W, Liu CW, Li SC, Wallace S, Podolof DA (1996) Assesment of tumor cell proliferation using [18F]fluorodeoxyadenosine and [18F]fluorouracile. J Pharm Sci 85:339–344
Marquez VE, Tseng CK-H, Mitsuya H, Aoki S, Kelly JA, H-jr F, Roth JS, Broder S, Johns DG, Driscoll JS (1990) Acid stable 2′-fluoro purine dideoxynuceosides as active agents against HIV. J Med Chem 33:978–985
Barchi JJ, Marquez VE, Driscoll JS, H-jr F, Mitsuya H, Shirasaka T, Aoki S, Kelly JA (1991) Potential anti-AIDS drugs. Lipophilic, adenosine deaminase-activated prodrugs. J Med Chem 34:1647–1655
Masood R, Ahluwalia GS, Cooney DA, Fridland A, Marquez VE, Driscoll JS, Hao Z, Mitauya H, Pemo CF, Broder S, Johns DG (1990) 2′-Flouro-2′, 3′-dideoxyarabinosyladenine: a metaboloically stable analogues of antiviral agent 2′, 3′- dideoxyarabinosyladenine. Mol Pharmacol 37:590–596
Hitchcock MJ, Woods K, DeBoeck H, Ho HT (1990) Biochemical pharmacology of 2-flouro-2′, 3′-dideoxyarabinofuranosyladenine, an inhibitor of HIV with improved metabolic and chemical stability over 2′, 3′-dideoxyadenosine. Antiviral Chem Chemother 1:319–327
Silverman RB (1988) In mechanism-based enzyme inactivation: chemistry and enzymology, vol 1. CRC, Boca Raton, p 59
Mitchell BS, Kelly WN (1980) Purinogenic immunodeficiency diseases: clinical features and molecular mechanisums. Ann Intern Med 92:826–831
Shewach DS, Mitchell BS (1989) Differential metabolism of 9-bta-d-arabinofuranosylguanine in human leukemic cells. Cancer Res 49:6498–6502
Leanza L, Ferraro P, Bianchi V (2008) Metabolic interrelations within guanine deoxynucleotide pools for mitochondrial and nuclear DNA maintenance. J Biol Chem 283:16437–16445
Kurtzberg J, Ernst TJ, keating MJ, Gandhi V, Hodge JP, Kisor DF, Lager JJ, Stephens C, Levin J, Kerenitsky T, Elion G, Mitchell BS (2005) Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 23:3396–3403
Curbo S, Karlsson A (2006) Nelarabine: a new purine analog in the treatment of hemtologic malignancies. Rev Recent Clin Trials 1:185–192
Radu CG, Shu CJ, Nair-Gill E, Shelly MS, Barrio JR, Satyamurthy N, Phelps ME, Witte ON (2008) Molecular imaging of lymphoid organs and immuneactivation by positron emission tomography with a new [18F]labeled 2′-deoxycytidine analog. Nat Med 14:783–788
Lyer M, Barrio JR, Namavari M, Bauer E, Satyamurthy N, Nguyen K, Toyokuni T, Phelps ME, Herschman HR, Gambhir SS (2001) 8-[18F]Fluoropenciclovir: an improved reporter probe for imaging HSV1-tk reporter gene expression in vivo using PET. J Nucl Med 42:96–105
Namavari M, Barrio JR, Toyokuni T, Gambhir SS, Cherry SR, Herschman HR, Phelps ME, Satyamurthy N (2000) Synthesis of 8-[18F]fluoroguanine derivatives: in vivo probes for imaging gene expression with PET. Nucl Med Biol 27:157–162
Barrio JR, Namavari M, Phelps ME, Satyamurthy N (1996) Regioselective fluorination of substituted guanines with dilute F2: a facile entry to 8- fluoroguanine derivatives. J Org Chem 61:6084–6085
Alauddin MM, Fissekis JD, Conti PS (2003) Synthesis of [18F]labeled adenosine analogues as potential PET imaging agents. J Label Compd Radiopharm 46:805–814
Pankieweiz KW, Krzeminiski J, Watanabe KA (1992) Synthesis of 2′-β-fluoro- and 3′-α-fluoro-substituted guanine nucleosides: effects of sugar conformational shifts on nucleophilic displacement of the 2′-hydroxy and 3′-hydroxy group with DAST. J Org Chem 57:7315–7321
Chatila T, Silverman L, Miller R, Geha R (1989) Mechanism of T cell activation by the calcium ionophore ionomycin. J Immunol 143:1283–1289
Reichman U, Watanabe KA, Fox JJ (1975) A practical synthesis of 2-deoxy-2-fluoro-d-arabinofuranose derivatives. Carbohydr Res 42:233–240
Tann CH, Brodfuehrer PR, Brundige SP, C-Jr S, Howell HG (1985) Fluorocarbohydrate in synthesis. An efficient synthesis of 1-(2-Deoxy-2-fluoro-β-d-arabinofuranosl)-5-iodouracil (β-FIAU) and 1-(2-Deoxy-2-fluoro-β-d-arabinofuranosl)thymine (β-FMAU). J Org Chem 50:3644–3647
Chu CK, Matulic-Aamic J, Huang JT, Chou TC, Bruchenal JH, Fox JJ, Watanabe KA (1989) Synthesis of 9-(-2-Deoxy-2-fluoro-b-d-arabinofuranosy)-9-H-purines and their biological activites. Chem Pharm Bull 37:336–339
Alauddin MM, Conti PS, Fissekis JD (2003) General synthesis of 2′-deoxy-2′-[18F]fluoro-1-β-d-arabinofuranosyluracil and its 5-substituted nucleosides. J Label Radiopharm 46:285–289
Cooper TM (2007) Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Ther Clin Risk Manage 3(6):1135–1141
Acknowledgements
This work was supported in part by NCI In Vivo Cellular Molecular Imaging Center grant P50 CA114747 (SSG). We also thank Dr. David Dick for the [18F] production, Dr. Frederick T. Chin for modification of a GE TRACERlab FX-FN synthetic module for radiosynthesis, and Dr. Jelena Levi for her review of the manuscript.
Conflict of interest disclosure
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Namavari, M., Chang, YF., Kusler, B. et al. Synthesis of 2′-Deoxy-2′-[18F]Fluoro-9-β-D-Arabinofuranosylguanine: a Novel Agent for Imaging T-Cell Activation with PET. Mol Imaging Biol 13, 812–818 (2011). https://doi.org/10.1007/s11307-010-0414-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11307-010-0414-x